Where Wellness & Culture Connect

Where Wellness & Culture Connect

Genentech Clinical Trials

  • A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

    Condition:
    Breast Cancer
    Drugs:
    Inavolisib, Fulvestrant
    Trial Name:
    WO43919
    Age:
    ≥18 Years
    Phase:
    3
    Learn More

  • A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

    Condition:
    Locally Advanced or Metastatic Breast Cancer
    Drugs:
    Giredestrant
    Trial Name:
    WO43571
    Age:
    ≥18 Years
    Phase:
    3
    Learn More

  • A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

    Condition:
    Hepatocellular Carcinoma (HCC)
    Drugs:
    Tiragolumab
    Trial Name:
    CO44668
    Age:
    ≥18 Years
    Phase:
    3
    Learn More

  • A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma

    Condition:
    Diffuse Large B-Cell Lymphoma
    Drugs:
    Glofitamab
    Trial Name:
    GO43693
    Age:
    ≥18 Years
    Phase:
    1
    Learn More

  • The Purpose of This Study is to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo as Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2‑Positive Locally Advanced or Metastatic Breast Cancer

    Condition:
    Metastatic Breast Cancer
    Drugs:
    Inavolisib
    Trial Name:
    WO44263
    Age:
    ≥18 Years
    Phase:
    3
    Learn More

  • A clinical trial to evaluate the safety and effectiveness of crovalimab in reducing pain crises, also called vaso-occlusive episodes (VOE), in people with sickle cell disease (SCD)

    Condition:
    Sickle Cell Disease
    Drugs:
    Crovalimab
    Trial Name:
    BO42451
    Age:
    ≥12 Years & ≤ 55 Years
    Phase:
    2
    Learn More

  • A Study Evaluating the Safety, Activity, and Pharmacokinetics of GDC-6036 in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

    Condition:
    Non-Small Cell Lung Cancer
    Drugs:
    GDC-6036
    Trial Name:
    BO44426
    Age:
    ≥18 Years
    Phase:
    1,2
    Learn More

  • Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer’s Disease

    Condition:
    Neurodegeneration – Alzheimer’s Disease
    Drugs:
    RO7126209
    Trial Name:
    BP42155
    Age:
    ≥ 50 Years & ≤ 85 Years
    Phase:
    1/2
    Learn More

  • A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

    Condition:
    Breast/Gyn
    Drugs:
    Atezolizumab, Trastuzumab Emtansine
    Trial Name:
    WO42633
    Age:
    ≥ 18 Years
    Phase:
    3
    Learn More

  • A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD)

    Condition:
    Hematology – Sickle Cell Disease
    Drugs:
    Crovalimab
    Trial Name:
    BO42452
    Age:
    ≥ 12 Years & ≤ 55 Years
    Phase:
    1
    Learn More

  • A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

    Condition:
    Hematology – 2L+ DLBCL, trFL, FL3B
    Drugs:
    Mosunetuzumab, Polatuzumab Vedotin
    Trial Name:
    GO43643
    Age:
    ≥ 18 Years
    Phase:
    3
    Learn More

  • A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)

    Condition:
    Neuroimmunology – Multiple Sclerosis
    Drugs:
    Fenebrutinib
    Trial Name:
    GN41851
    Age:
    ≥ 18 Years & ≤ 55 Years
    Phase:
    3
    Learn More

  • A clinical trial to compare the drug combination mosunetuzumab plus lenalidomide with the drug combination rituximab plus lenalidomide in people with previously treated follicular lymphoma

    Condition:
    Hematology – 2L+ Follicular lymphoma
    Drugs:
    Mosunetuzumab, Lenalidomide
    Trial Name:
    GO42909
    Age:
    ≥ 18 Years
    Phase:
    3
    Learn More

  • A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

    Condition:
    Respiratory and Allergy – COPD
    Drugs:
    Astegolimab
    Trial Name:
    GB44332
    Age:
    ≥ 40 Years & ≤ 80 Years
    Phase:
    3
    Learn More

  • A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

    Condition:
    Nephrology & Rheumatology – Membranous Nephropathy
    Drugs:
    Obinutuzumab
    Trial Name:
    WA41937
    Age:
    ≥ 18 Years & ≤ 75 Years
    Phase:
    3
    Learn More

  • A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis

    Condition:
    Nephrology & Rheumatology – Systemic Lupus Eythematosus
    Drugs:
    Obinutuzumab
    Trial Name:
    WA42985
    Age:
    ≥ 12 Years & ≤ 17 Years
    Phase:
    2
    Learn More

  • A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

    Condition:
    Nephrology & Rheumatology – Systemic Lupus Eythematosus
    Drugs:
    Obinutuzumab
    Trial Name:
    CA42750
    Age:
    ≥18 Years & ≤ 75 Years
    Phase:
    3
    Learn More

Copyright © 2023, BlackDoctor, Inc. All rights reserved.